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Objectives: Health disparities and inequalities in access to care among different socio-
economic, ethnic, and racial groups have been well documented in the U.S. healthcare 
system. In this review, we aimed to provide an overview of barriers to care contributing 
to health disparities in gynecological oncology management and to describe site-specific 
disparities in gynecologic care for endometrial, ovarian, and cervical cancer.
Methods: We performed a literature review of peer-reviewed academic and govern-
mental publications focusing on disparities in gynecological care in the United States by 
searching PubMed and Google Scholar electronic databases.
Results: There are multiple important underlying issues that may contribute to the dis-
parities in gynecological oncology management in the United States, namely geographic 
access and hospital-based discrepancies, research-based discrepancies, influence of 
socioeconomic and health insurance status, and finally the influence of race and bio-
logical factors. Despite the reduction in overall cancer-related deaths since the 1990s, 
the 5-year survival for Black women is significantly lower than for White women for each 
gynecologic cancer type and each stage of diagnosis. For ovarian and endometrial 
cancer, black patients are less likely to receive treatment consistent with evidence-based 
guidelines and have worse survival outcomes even after accounting for stage and 
comorbidities. For cervical and endometrial cancer, the mortality rate for black women 
remains twice that of White women.
Conclusion: Health care disparities in the incidence and outcome of gynecologic 
cancers are complex and involve biologic factors as well as racial, socioeconomic, 
and geographic barriers that influence treatment and survival. These barriers must be 
addressed to provide optimal care to women in the U.S. with gynecologic cancer.
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iNTRODUCTiON
The Institute of Medicine released a landmark report in 2003 titled “Unequal Treatment: Confronting 
Racial and Ethnic Disparities in Health Care,” which demonstrated disparities in the U.S. health care 
system between treatment of racial and ethnic minorities and Whites, subsequently resulting in 
poorer health outcomes for millions of Americans (1).
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Since that time, the National Cancer Institute (NCI) through 
the Center to Reduce Cancer Health Disparities (CRCHD), 
the American Cancer Society, the American Society of Clinical 
Oncology, and the Society of Gynecologic Oncology has com-
mitted to the goals of eliminating disparities in cancer-related 
outcomes (2–4). The NCI defines cancer health disparities as 
“differences in the incidence, prevalence, mortality, and burden 
of cancer and adverse related conditions that exist among specific 
population groups in the United States (2).”
The etiology of disparities in cancer treatment and outcomes 
has been linked to the complex interplay of race/ethnicity, 
cultural, socioeconomic, and educational factors. Geographic 
variability in provider and hospital standards and biological dif-
ferences between ethnic groups must also be considered (1, 4, 5). 
Finally, variation from evidenced-based treatment guidelines has 
been indicated as a modifiable factor that can result in poorer 
survival outcomes (6).
This review aims to describe some of the important underly-
ing issues that may contribute to the disparities in gynecological 
oncology management in the United States, namely geographic 
access and hospital-based discrepancies, research-based dis-
crepancies, influence of socioeconomic and health insurance 
status, and finally the influence of race. This review continues 
with detailing site-specific disparities in gynecologic care for 
endometrial, ovarian, and cervical cancer.
GeOGRAPHiC ACCeSS AND  
HOSPiTAL-BASeD DiSCRePANCieS
A growing body of evidence has demonstrated the importance 
of access to high-volume hospitals and providers for optimal 
management and outcomes related to gynecologic malignancies. 
Several studies have demonstrated worse survival outcomes 
associated with low volume hospital centers and providers (6–9). 
A recent analysis of 96,000 patients with ovarian cancer identified 
by the National Cancer Data Base demonstrated 56% of patients 
were not receiving the standard of care as designated by the 
National Comprehensive Cancer Network (NCCN) guidelines. 
The study also demonstrated that 25% of women received care 
at very low volume institutions, defined as those treating one to 
seven cases of ovarian cancer annually. The authors concluded 
that deviation from NCCN guidelines and treatment at very low 
volume institutions were both independent predictors of worse 
disease-specific overall survival (hazard ratio 1.33, 95% CI 1.26–
1.41 and HR 1.08, 95% CI 1.01–1.16, respectively) (6, 7). A prior 
study had also demonstrated that lower volume centers were less 
likely to provide recommended comprehensive surgical staging 
procedures (10). An analysis of Surveillance, Epidemiology, End 
Results (SEER) database demonstrated that chemotherapeutic 
treatments also varied depending on geography and available 
oncological providers (11, 12). Per the US Census Bureau, 81% 
of people live in cities or suburbs with 19% living in rural areas. 
Shalowitz et al. recently reported that an estimate 7663 women 
with gynecological malignancies (9% of the total cases of gyneco-
logical cancers per year) live in low-access counties in the US 
located 50 miles from the nearest gynecologic oncologist. These 
counties were more likely be rural, have residents with lower 
median incomes, and have more White and Hispanic patients 
than counties in closer proximity to gynecologic oncologists 
(13). Although this study did not include outcomes data, prior 
studies have reported that treatment by a trained gynecological 
oncologist with increased operative volume yields favorable sur-
vival outcomes (14–17). Other studies also associated increasing 
distance from a gynecological oncologist with increased cervical 
and endometrial cancer mortality (18). It is therefore important 
to consider geographic and hospital system-related disparities 
which influence both access to care and adherence to evidence-
based treatment guidelines.
ReSeARCH-BASeD DiSCRePANCieS
Given varied survival outcomes among minority patients, there 
has been increased focus on attempting to recruit minorities for 
clinical trials to elucidate inherent differences in tumor biology, 
response to therapy, and survival in clinical situations where 
treatment regimens are controlled between groups. The National 
Institutes of Health (NIH) Revitalization Act of 1993 specifically 
addressed this issue encouraging enrollment of women and 
minorities to NIH-sponsored research. However, upon analysis of 
the four most common NCI-funded clinical trials (breast, prostate, 
colorectal, and lung cancers) from 1996 through 2002, investiga-
tors found that although clinical trial enrollment rate increased 
by almost 50% during this time period, the proportion of trial 
participants who were non-White actually declined – Hispanic 
patients from 3.7% of trial participants to 3.0% and Black patients 
from 11.0% of trial participants to 7.9% (19). It is not surprising 
that decreased minority enrollment in clinical trial also exists for 
gynecologic cancers. Scalici et al. recently published their paper 
on minority participation in 170 Gynecologic Oncology Group 
(GOG) trials from 1994 to 2013. They reported that of a total 
of 45,259 patients were included in GOG trials with 83% being 
White, 8% Black, and 9% other (p < 0.01). They also used Center 
for Disease Control (CDC) age-adjusted incidence to determine 
that observed enrollment of Black patients was 15 times lower than 
expected for ovarian cancer trials, 10 times lower than expected 
for endometrial cancer trials, 4.5 times lower than expected for 
cervical cancer trials, and 5.2 times lower than expected for 
sarcoma trials (p < 0.001) irrespective of the type of study or year 
published (20). Scalici et  al. also found that African American 
participation in clinical trials actually decreased from 16% from 
1994 to 2002 to 6% from 2009 to 2013. A recent review utilizing 
qualitative interviews concluded that the key barriers to minority 
recruitment to clinical trials were lack of opportunities to par-
ticipate and lack of encouragement to enroll (21). Additionally, 
language barriers and logistical issues such as cost of travel may 
play a role in the recruitment of some minority populations (22). 
Prior studies have implicated a reduced acceptance to enrollment 
due to minority skepticism as a factor for reduced involvement 
in clinical trials (21, 23, 24). However, a study evaluating clinical 
trial consent rates by race demonstrated no difference in the will-
ingness of Blacks and Hispanics to participate in health research 
compared to non-Hispanic Whites when offered clinical trial 
enrollment (25). To fully understand and optimize treatment for 
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minority patients, it is imperative that these issues be addressed. 
The NRG Oncology Accrual Workshop recently held a meeting to 
increase minority recruitment for clinical trials (26).
SOCiOeCONOMiC STATUS AND HeALTH 
iNSURANCe STATUS
Individuals with lower socioeconomic status have disproportion-
ately higher cancer incidence rates and death rates than those with 
higher socioeconomic status, regardless of demographic factors 
such as race/ethnicity (27). According to the US Census Bureau’s 
report on Income and Poverty for 2014, the median household 
income in the US was $53,657 with significant variation by race, 
with Asians the highest at $74,297, and Blacks the lowest at 
$35,398 (28). The official poverty rate was 14.8%, accounting for 
46.7 million people. In 2014, women made an average 79% of 
what men earned with a median income of $39,621 compared to 
$50,383 earned by men. Sixteen percent of women were below the 
poverty line, compared to 13.4% of males. Gender differences in 
poverty rates were more pronounced for those aged 65 and older 
(12.1% for women vs. 7.4% for men). Ten percent of non-Hispanic 
Whites, 12.0% of Asians, 26.2% of Blacks, and 23.6% of Hispanics 
lived below the poverty level (29). The US Census Bureau’s report 
of Health Insurance Coverage in the US reported the percentage 
of people without health insurance coverage decreased by 10.4%, 
or 33.0 million in 2013, compared to the number of uninsured in 
2013. Despite these great strides in providing health insurance in 
the US, Blacks and Hispanics still have a higher rate of uninsured 
individuals compared to Asians and non-Hispanic Whites (11.8 
and 19.9% vs. 9.3 and 7.6%, respectively). Additionally, 16.6% of 
uninsured individuals earned <$25,000 per year (30). Individuals 
in lower socioeconomic groups often present with advanced stage 
disease and are less likely to receive standard regimens of treat-
ment (31).
A recent study by Bristow et al. evaluating the SEER-Medicare 
database for advanced ovarian cancer found poorer adherence to 
NCCN treatment guidelines associated with low socioeconomic 
status [OR 1.32, 95% CI (1.14–1.52)] and worse survival when 
accounting for the effects of other variables [HR 1.25, 95% CI 
(1.17–1.34)] despite equivalent Medicare insurance status (32). 
Additionally, insurance status seems to affect the type of care pro-
vided. Goff et al. demonstrated that payer status (private insurance 
vs. Medicaid) significantly impacted the chance of undergoing 
optimal surgical management in ovarian cancer (14). Esselen 
et  al. demonstrated that Black women and uninsured women/
women with Medicaid were less likely to undergo minimally 
invasive hysterectomies for uterine or cervical cancer after analy-
sis of 46,450 women identified by the National Inpatient Sample 
(33). In a previous study by Harlan et al. examining 11 different 
cancer types, investigators noted significantly lower adherence to 
treatment guidelines for Black patients with Medicaid compared 
to Black patients with Medicare or private insurance (27). The 
same investigators found lack of private insurance a barrier to 
guideline based treatment for Black and Hispanic women with 
ovarian cancer, suggesting health insurance status may serve as 
proxy for other socioeconomic factors (34). Similarly, another 
analysis of adherence to NCCN guidelines in patients with ovar-
ian cancer identified through the National Cancer Data Base 
demonstrated median household income of less than $35,000 
was associated with non-adherence to evidence-based guidelines 
(OR 1.26, 95% CI 1.21–1.32) and worse survival (HR 1.06, 95% 
CI 1.02–1.1) (35). These findings were consistent with prior 
studies that have linked poverty level and low socioeconomic 
status to poorer adherence to evidence-based treatments and 
worse ovarian cancer survival (36–38). In addition to treatment 
administration, a recent evaluation of 8211 elderly patients with 
ovarian cancer identified from the SEER database demonstrated 
a decreased chance of hospice referral associated with non-White 
race [OR 1.44; 95% CI (1.26–1.65), p < 0.001], the lowest income 
group [OR 1.17; 95% CI (1.04–1.32), p =  0.01], and Medicare 
fee-for-service (vs. managed care) [OR 1.39; 95% CI (1.24–1.56), 
p < 0.001] (39).
RACe
Per the US Census Bureau, as of 2015, there are 321,729,000 
people living in the United States with approximately 63.7% of 
the population described as Non-Hispanic White, 16.4% of the 
population described as Hispanic or Latino, 12.2% of the popula-
tion described as African American, 4.7% Asian, and 0.9% Native 
American, Hawaiian, or Alaskan Native. Black men and women 
are more likely to die from cancer than any racial or ethnic group 
(31). Despite the reduction in overall cancer-related deaths since 
the 1990s, the 5-year survival for Black women is significantly 
lower than for White women at each stage of diagnosis, with the 
gap in survival actually increasing over the past few decades (40). 
Although the incidence of a new cancer diagnosis per 100,000 
individuals is lower for Black women than White women (391.7 
vs. 418.3, OR 0.94, p < 0.05), the death rate per 100,000 individuals 
is higher (180.6 for Blacks vs. 155.0 for Whites, OR 1.17, p < 0.05) 
(40). Interestingly, for all cancer sites, Hispanic women had a 
lower incidence of cancer relative to non-Hispanic White women 
[333.2 per 100,000 individuals compared to 433.9 per 100,000 
(RR 0.8, p <  0.05)]. Additionally, for all cancer sites, Hispanic 
women had a favorable prognosis compared to non-Hispanic 
women with a mortality rate of 100.5 per 100,000 compared to 
154.7 per 100,000 (RR 0.6, p < 0.05) (41). A notable exception is 
cervical cancer, where the incidence per 100,000 individuals for 
Hispanics was 11.8, compared to 7.2 for non-Hispanic Whites 
(RR 1.6, p <  0.05) and the mortality rate was 3.0 per 100,000 
for Hispanics and 2.1 per 100,000 non-Hispanic Whites (RR 1.5, 
p <  0.05) (41). In general, Asian women had lower incidence 
and mortality rates than non-Hispanic White women across all 
cancer types (42–44). Among all Asians, the incidence of cancer 
per 100,000 is 314.9 with a mortality rate of 115.5 per 100,000, 
which is notably lower than that for non-Hispanic Whites (477.5 
and 190.7, RR 0.7 and RR 0.6, p < 0.05, respectively) (45).
OvARiAN CANCeR
Epithelial ovarian cancer (EOC) is the fifth cause of cancer death 
among women in the United States, accounting for an estimated 
21,290 new cases and 14,180 cancer deaths in the US in 2015 
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(31). With aggressive surgical and chemotherapeutic manage-
ment, overall survival has improved from 36% during the period 
of 1975–1977 to 45% during the period 2004–2010 (p < 0.05). 
However, the survival rate over the same time period for Black 
women has actually decreased from 42 to 36% (46). From 2002 to 
2011, the mortality rate associated with ovarian cancer decreased 
significantly by 2% per year among White women, 1.4% per year 
among Hispanic women, but remained unchanged among Black 
women (47).
Several studies have demonstrated that worse survival 
outcomes among the Black population results from barriers 
that impede access to quality care and standardized evidence-
based surgical and adjuvant treatment (32, 36, 48). Although 
the incidence of ovarian cancer is higher among White women 
(12.8 new cases per 100,000) compared to Black women (9.8 
new cases per 100,0000), Black women tend to present with 
more advanced stage ovarian cancer compared to White women 
(49, 50). Black women have a higher incidence of medical 
comorbidities compared to White women that may influence 
treatment decisions (51, 52). However, several studies evaluat-
ing large nationally representative databases have demonstrated 
that Black patients are less likely to receive treatment consistent 
with evidence-based guidelines and have worse survival out-
comes even after accounting for stage and comorbidities (32, 36, 
37, 53). Parham et al. found that Black patients were less likely to 
receive combined surgery and chemotherapy treatment (48). In 
an analysis of a state specific database, Bristow et al. found that 
compared to White patients, Black race was associated with a 
statistically significant and independent lower likelihood of hys-
terectomy, lymphadenectomy, bowel resection, and surgery by a 
high-volume surgeon (54). Goff et al. also found that Black and 
Hispanic patients were also less likely to receive comprehensive 
staging compared to White patients (14). A SEER analysis by 
Wright et al. demonstrated delayed administration of adjuvant 
chemotherapy in Black patients, which was associated with an 
increased mortality rate (55). Importantly, the difference in 
survival outcomes among races is reduced or eliminated after 
accounting for access issues, socioeconomic status, stage, and 
treatment (4). The similarity in survival outcomes is highlighted 
in several GOG clinical trials where Black and White women 
receive similar treatments (56, 57). After review of available 
literature, it appears that equal treatment yields equivalent sur-
vival outcomes for both Black and White patients with ovarian 
cancer (4).
eNDOMeTRiAL CANCeR
Endometrial cancer is the most common gynecologic cancer in 
the US accounting for 54,870 new cases and 10,170 deaths in 
2015 (31). For all stages, the 5-year survival rate is 82%, 95% 
for local disease, 68% for regional disease, and 18% for distant 
metastatic disease (31). White women had the highest incidence 
of endometrial cancer compared to other ethnic groups (24.8 
per 100,000); however, the mortality rate is twice as high for 
Black women (7.3 per 100,000 vs. 3.9 per 100,000) (58). The 
5-year survival for White women from 2004 to 2010 was 85% 
compared to 65% for Black women over the same time period 
(46). Similar to ovarian cancer, several studies have attributed 
this difference in survival to inequalities in access to care, 
adherence to evidence-based treatment guidelines, and socio-
economic barriers (59, 60). Unlike ovarian cancer, there may 
be inherent differences in tumor biology between White and 
Black patients with endometrial cancer as equal treatment has 
not correlated with equal outcomes (4). Black patients tend to be 
diagnosed at higher stages, with higher grade lesions, and high-
risk histologies (61–65). Although worse tumor characteristics 
are associated with worse overall survival, after accounting for 
all histopathologic and sociodemographic factors, several large 
database analyses demonstrated worse survival associated with 
Black race (66–70). Black patients are less likely to be treated 
for advanced disease and less likely to undergo surgery (62, 
71–73). However, Black women are more likely to be treated at 
high volume institutions with high volume specialized surgeons 
(74). When staging lymphadenectomy was performed, there 
were similar rates between Blacks and Whites (64). Other stud-
ies have demonstrated similar use of adjuvant chemotherapy 
and radiotherapy (73). Despite similar treatment, worse overall 
survival persists among Black women with endometrial cancer. 
In a GOG randomized clinical trial for advanced and recurrent 
endometrial cancer, Black women had a 26% greater chance of 
death compared to White women despite similar surgical and 
chemotherapeutic treatments after controlling for prognostic 
factors (75). Several studies have evaluated molecular differences 
in tumors from Black and White women in effort to identify why 
Black women have poorer prognosis relative to White women. 
These studies have primarily focused on p53 mutations, HER2/
neu expression, and PTEN mutations. Mutations in tumor sup-
pressor gene p53 have been associated with non-endometrioid 
histology, high grade tumors, advanced stage at presentation, 
and poorer overall survival (76). Clifford et  al. demonstrated 
that Black women with stage I tumors were three times more 
likely to overexpress mutant p53, associated with worse survival 
and higher recurrence rates (77). Santin et  al. demonstrated 
threefold higher HER2/neu expression in Black patients with 
serous endometrial cancer than in White patients with the same 
histology. The investigators concluded that overexpression of 
Her2/neu was an independent variable associated with poorer 
survival outcomes (78). Maxwell et  al. demonstrated fewer 
PTEN mutations, associated with better outcomes and endo-
metrioid histology, among Black patients compared to White 
patients (79). Further genetic and molecular studies need to 
be performed to further elucidate the causes of worse overall 
prognosis of Black patients with endometrial cancer.
CeRviCAL CANCeR
Cervical cancer is the fourth most common cancer in the world. 
In the US, with the success of cervical cancer screening, the annual 
incidence is 12,900 with 4,100 deaths in 2015 (31). In 2015, the 
incidence of cervical cancer for Blacks was 11.4 per 100,000, 13.8 
per 100,000 for Hispanics, and 8.5 per 100,000 for non-Hispanic 
Whites. The mortality rate was 4.9 per 100,000 for Blacks, 3.3 per 
100,000 for Hispanics, and 2.3 per 100,000 non-Hispanic Whites 
(80). The overall 5-year survival for cervical cancer from 2004 to 
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2010 among White women was 71% compared to 62% in Black 
women (31). Interestingly, although the mortality rate is higher for 
Hispanics compared to non-Hispanic Whites, the 5-year survival 
for cervical cancer is 75% among Hispanic women compared 
to 71% for non-Hispanic Whites (41). Disparities in cervical 
cancer incidence and mortality are a direct reflection of unequal 
access to prevention, screening, and ultimate treatment. Data 
from the National Immunization Survey demonstrated a lower 
rate of HPV vaccination among Black and Hispanic adolescent 
girls compared to White adolescent girls (81). Although Black 
adolescents were more likely to initiate HPV immunization, they 
were less likely to complete the three-dose injection series (82, 
83). Congress passed the Breast and Cervical Cancer Mortality 
Prevention Act of 1990, which allowed low-income, uninsured, 
and underinsured women to gain access to breast and cervical 
cancer screening and diagnostic services. Overall, 83% of women 
who have not had hysterectomies reported having a Pap smear in 
the prior 3 years, including 85% of Black women, 83.5% of White 
women, and 79% of Hispanic women (84). Despite the relative 
success with initiating screening, differences in follow-up from 
abnormal cervical cytology remains an issue, with Black women 
the most likely to be lost to follow-up (85). Consequently, Black 
women were more likely to present with more advanced disease 
than White women (31).
Additionally, treatment differences related to race have been 
shown to play a role in outcome disparities. Black women were 
less likely to receive a radical hysterectomy than White women 
for early stage cervical cancer (86) and were less likely to receive 
intra-cavity radiation therapy for locally advanced disease (87). 
Farley et al. demonstrated that in an equal access environment 
with identical treatment for cervical cancer between White and 
Black patients, there was equivalent 5- and 10-year survival data 
between races, reinforcing the idea that equal care results in equal 
survival outcomes in cervical cancer (88).
CONCLUSiON
Health care disparities in the incidence and outcome of 
gynecologic cancers persist and, in some cases, are worsening. 
The explanation for these disparities is complex and involves 
racial, economic, geographic, and biologic factors that influ-
ence treatment and survival. Much of the information available 
outlining these disparities have focused on disparities between 
Black and White women, with limited studies available regarding 
other minority populations. Additionally, as most of the studies 
investigating health disparities evaluated large nationally repre-
sentative databases with limited detailed clinical information, it 
is not possible to account for other confounding factors that may 
have influenced treatment decisions or deviations from evidence-
based guidelines. Despite diagnostic and therapeutic advances 
that have resulted in improved survival among American women 
in general, significant barriers exist in providing optimal care 
to millions of women in the US with gynecologic cancer. While 
not all factors involved in healthcare disparities are modifiable, 
identification and elimination of those that are must be a consid-
ered a top priority in a country that considers access to quality 
healthcare a basic human right.
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